DOTA-PSMA-EB-01
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM) .DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors[1]. DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
Product Specifications
Product Name Alternative
LNC1003
UNSPSC
12352209
Target
PSMA; Radionuclide-Drug Conjugates (RDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-psma-eb-01.html
Purity
97.02
Solubility
DMSO : 6.67 mg/mL (ultrasonic)
Smiles
CC1=C(C=CC(C2=CC(C)=C(C=C2)NC([C@@H](NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)CCCCNC(CCOCCOCCC(NC[C@H]4CC[C@@H](CC4)C(N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC5=CC=C6C=CC=CC6=C5)=O)=O)=O)=O)=C1)/N=N/C7=C(C8=C(C(S(=O)(O)=O)=CC(S(=O)(O)=O)=C8N)C=C7)O
Molecular Formula
C87H115N15O28S2
Molecular Weight
1883.06
References & Citations
[1]Wen X, et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023 Jul;50 (9) :2846-2860.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
RDC Peptide
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV729120 1.0 µg DNA
ICCA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
Sign In for Pricing
View Details 
